Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19221743 | 0.92 | MAPT (0.58) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL16569991 | 0.84 | MAPT (0.66) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL29225369 | 0.81 | MAPT (0.65) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL7293241 | 0.81 | MAPT (0.62) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL5105829 | 0.80 | MAPT (0.58) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL29772033 | 0.79 | SIRT6 (0.58) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL6133189 | 0.79 | MAPT (0.56) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL27950762 | 0.79 | MAPT (0.70) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL27774 | 0.79 | MAPT (1.00) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL6714560 | 0.79 | MEN1 (0.73) | MAPTALDH1A1LMNASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102827082-A | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO CO LTD | 2012-12-19 | — | — | CN | disclosed |
| CN-1976938-B | Thienopyrazole derivatives having PDE7 inhibitory activity | DAIICHI SANKYO CO LTD | 2012-08-15 | — | — | CN | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| CN-1976938-A | Thienopyrazole derivatives having PDE7 inhibitory activity | ASUBIO PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135442-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | MAPT 3096/4885ALDH1A1 1546/4885LMNA 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.